Related Experiment Video
Updated: Nov 13, 2025
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Current and emerging pharmacotherapy for Gaucher disease in pediatric populations
Richard Sam1, Emory Ryan1, Emily Daykin1
1Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, United States of America.
Insights
New therapies like gene therapy and small molecule chaperones offer hope for children with Gaucher disease (an inherited enzyme deficiency). These treatments aim to cure systemic and central nervous system manifestations, improving outcomes for pediatric patients.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Medicine
Background:
- Gaucher disease is an inherited lysosomal storage disorder caused by glucocerebrosidase deficiency.
- Significant health improvements in Gaucher disease patients are attributed to enzyme replacement and substrate reduction therapies.
- Early diagnosis and treatment initiation are critical for optimal outcomes, particularly in pediatric populations.
Purpose of the Study:
- To review the effectiveness of current Gaucher disease therapies.
- To describe novel pharmacotherapies under development for Gaucher disease, with a focus on pediatric patients.
Main Methods:
- Literature review of existing and emerging Gaucher disease treatments.
- Analysis of therapeutic strategies for both non-neuronopathic and neuronopathic forms of Gaucher disease in children.
Main Results:
- Emerging options for non-neuronopathic Gaucher disease include gene therapy and small molecule glucocerebrosidase chaperones.
- These novel therapies may offer a cure for systemic manifestations and improve treatment accessibility.
- For neuronopathic Gaucher disease, research focuses on central nervous system targeting strategies.
Conclusions:
- Pediatric patients with Gaucher disease face promising new therapeutic avenues.
- Advanced treatments like brain-targeted gene therapy and chaperones are being explored for neuronopathic forms.
- The development of these therapies signifies an exciting era for managing Gaucher disease and other lysosomal storage disorders.
Introduction:
The past decades have witnessed a remarkable improvement in the health of patients with Gaucher disease, the inherited deficiency of the lysosomal enzyme glucocerebrosidase, resulting from the availability of enzyme replacement and substrate reduction therapies. Especially in pediatric populations, early diagnosis and initiation of treatment is essential to achieving optimal outcomes.
Areas Covered:
The authors review the literature pertaining to the effectiveness of currently available therapies and describe new pharmacotherapies under development, especially for young patients.
Expert Opinion:
For pediatric patients with non-neuronopathic Gaucher disease, there may be new therapeutic options on the horizon in the form of gene therapy or small molecule glucocerebrosidase chaperones. These have the potential to result in a cure for systemic disease manifestations and/or to reduce the cost and convenience of treatment. For children with neuronopathic Gaucher disease, the challenge of targeting therapy to the central nervous system is being explored through new modalities including brain-targeted gene therapy, in-utero therapy, brain-penetrant small molecule chaperones, and other methods that convey enzyme across the blood-brain barrier. Indeed, these are exciting times for both pediatric patients with Gaucher disease and those with other lysosomal storage disorders.
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
01:28Drug Therapy
Antianxiety Medications